All CD30L reagents are produced in house and quality controlled, including 2 CD30L Antibody, 51 CD30L Gene, 6 CD30L Lysate, 6 CD30L Protein, 2 CD30L qPCR. All CD30L reagents are ready to use.
Recombinant CD30L proteins are expressed by HEK293 Cells with fusion tags as N-human IgG1-Fc, N-His, N-cleavage.
CD30Lantibodies are validated with different applications, which are ELISA.
CD30LcDNA clones are full length sequence confirmed and expression validated. There are 13 kinds of tags for each CD30L of different species, especially GFP tag, OFP tag, FLAG tag and so on. There are three kinds of vectors for choice, cloning vector, expression vector and lentivrial expression vector.
CD30 ligand (CD30L), also known as CD153 and TNFSF8, is a membrane-associated glycoprotein belonging to the TNF superfamily and TNFR superfamily, and is a specific ligand for CD30/TNFRSF8 originally described as a cell surface antigen and a marker for Hodgkin lymphoma and related hematologic malignancies. CD30L is a type-II membrane glycoprotein expressed on activated T cells, stimulated monocyte-macrophages, granulocytes, eosinophils, and some Burkitt-like lymphoma cell lines. CD30L is capable of transducing signals through CD30 on different CD30+ lymphoma cell lines, and mediates pleiotropic biologic effects including cell proliferation, activation, differentiation, as well as cell death by apoptosis. CD30-CD30 ligand interaction has been suggested to have a pathophysiologic role in malignant lymphomas, particularly Hodgkin disease, large cell anaplastic lymphomas and Burkitt lymphomas, and is also involved in activation and functioning of the T cell-dependent immune response. Thus, CD153 and its receptor CD30 are regarded as therapeutic targets in hematologic malignancies, autoimmune and inflammatory diseases.